Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceuticals North America has announced the availability of Uloric by prescription in pharmacies across the US for the chronic management of hyperuricemia in patients with gout.
Subscribe to our email newsletter
According to the company, this once-daily oral medication, available in 40mg and 80mg tablets, is the first new treatment option for hyperuricemia in patients with gout in more than 40 years.
Uloric was discovered by Teijin Pharma and licensed to Takeda for the US market.
Uloric was studied and evaluated in multiple clinical trials involving more than 4,000 subjects, in some for up to five years. The pivotal, Phase III clinical trial, Confirms, demonstrated that Uloric 80mg was superior to Uloric 40mg and allopurinol 300/200mg (67%, 45% and 42%, respectively) at achieving serum uric acid levels of less than 6mg/dl at the final visit (both p<0.001).